trl1068
mAbexperimental
Clinical trial activity
3 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 8, 2021 (NCT04763759)
Timeline
Indications
Mechanism of action
- Replicative DNA helicaseBINDING AGENT
dnaB binding agent
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314660 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06621251 | Phase 2 | Jan 1, 2025 | Trellis Bioscience LLC |
| NCT05355207 | Phase 1 | Jan 31, 2023 | Trellis Bioscience LLC |
| NCT04763759 | Phase 1 | Feb 8, 2021 | Department of Health and Human Services, LifeBridge Health, Phoenix Clinical Research Center, The University of Texas, Dallas, Trellis Bioscience LLC, University of Alabama, Birmingham, University of California, Los Angeles, University of Florida, University of Southern California, University of Virginia, Wellcome Trust |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Trellis Bioscience LLC | For profit | 3 | 3 | 2 | 2021 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2021 |
| LifeBridge Health | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Phoenix Clinical Research Center | For profit | 1 | 0 | 1 | 2021 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Florida | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Virginia | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2021 |
11 organizations
Page 1 / 1